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Brucellosis is a highly zoonotic disease that affects animals and human beings. Brucella suis is the etiological agent of porcine
brucellosis and one of the major human brucellosis pathogens. Laboratory diagnosis of porcine brucellosis mainly relies on sero-
logical tests, and it has been widely demonstrated that serological assays based on the detection of anti O-polysaccharide anti-
bodies are the most sensitive tests. Here, we validate a recombinant glycoprotein antigen, an N-formylperosamine O-polysaccha-
ride–protein conjugate (OAg-AcrA), for diagnosis of porcine brucellosis. An indirect immunoassay based on the detection of
anti-O-polysaccharide IgG antibodies was developed coupling OAg-AcrA to enzyme-linked immunosorbent assay plates (glyco-
iELISA). To validate the assay, 563 serum samples obtained from experimentally infected and immunized pigs, as well as animals
naturally infected with B. suis biovar 1 or 2, were tested. A receiver operating characteristic (ROC) analysis was performed, and
based on this analysis, the optimum cutoff value was 0.56 (relative reactivity), which resulted in a diagnostic sensitivity and spec-
ificity of 100% and 99.7%, respectively. A cutoff value of 0.78 resulted in a test sensitivity of 98.4% and a test specificity of 100%.
Overall, our results demonstrate that the glyco-iELISA is highly accurate for diagnosis of porcine brucellosis, improving the di-
agnostic performance of current serological tests. The recombinant glycoprotein OAg-AcrA can be produced in large homoge-
neous batches in a standardized way, making it an ideal candidate for further validation as a universal antigen for diagnosis of
“smooth” brucellosis in animals and humans.
Brucella spp. are Gram-negative facultative intracellular bacte-ria responsible for brucellosis in humans and animals. Animal
brucellosis has a major economic impact because the infection
causes abortions and stillbirths and reduces fertility in herds, while
brucellosis in humans is a debilitating disease characterized by
fever, sweating, and pain (1, 2).Brucella suis is the etiological agent
of porcine brucellosis and one of the main human brucellosis
pathogens, together with Brucella melitensis and Brucella abortus.
There are five biovars of B. suis, with biovars 1, 2, and 3 being
responsible for porcine brucellosis (3). B. suis biovars 1 and 3,
endemic in Asia and America, are highly zoonotic and cause seri-
ous reproductive problems in pigs (infertility, abortion, and or-
chitis) and a serious disease in humans. Biovar 2 is restricted to
Europe, where it represents an emerging problem with a high
economic impact in pig farms and is less pathogenic for humans.
In the absence of an effective porcine brucellosis vaccine, con-
trol of the disease in pigs depends exclusively on detection and
slaughter of infected animals. The gold standard method for con-
firmation of the infection is isolation of the pathogen; however,
the slow growth of brucellae in primary cultures (up to 7 days), the
risk involved in their handling, and the poor sensitivity of the
method make diagnosis based solely on isolation of brucellae in-
effective, not always feasible, and expensive. Therefore, laboratory
diagnosis of porcine brucellosis mainly relies on serological tests
using serum samples. Currently, all these tests are based on those
that have been developed for the diagnosis of bovine brucellosis.
The most commonly used serological tests are agglutination tests,
such as the buffered plate agglutination test (BPAT) and Rose
Bengal plate agglutination test (RBT), the complement fixation
test (CFT), the fluorescence polarization assay (FPA), and com-
petitive (cELISA) and indirect (iELISA) enzyme-linked immu-
nosorbent assays (4, 5). With the exception of FPA and cELISA,
which measure specific antibodies against the immunodominant
O-polysaccharide section of lipopolysaccharide (LPS), all these
tests use as antigens whole bacteria or bacterial extracts enriched
in smooth or rough LPS, which are composed of a complex mix-
ture of antigens (6, 7). Therefore, current serological tests suffer
from false-positive reactions due to cross-reactivity with other
antigens and/or common epitopes present in the lipid A and core
sections of LPS. Additionally, a number ofGram-negative bacteria
that possess similar O-polysaccharide structures (e.g., Escherichia
coli O157 and Yersinia enterocolitica O:9) may induce antibodies
that cross-react withBrucella antigens, causing false-positive reac-
tions. Finally, a problem still unsolved in the serodiagnosis of bru-
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cellosis is the lack of a standardized reference antigen for diagnosis
of the disease (8).
Since the identification and characterization of the N-glycosy-
lation machinery of Campylobacter jejuni, the prototypical bacte-
rial glycosylation system (9–12), and its functional transfer to E.
coli (13), bacterial glycoengineering has emerged as a new disci-
pline to produce recombinant glycoproteins that can be used as
therapeutics, vaccines, or antigens for diagnosis (14–17). It has
been largely demonstrated that the C. jejuni N-oligosaccharyl-
transferase (OTase) PglB (PglBCj), because of its low substrate
specificity, can transfer a range of different LPSO-polysaccharides
from its lipid donor to carrier proteins in a system that combines
the N-glycosylation system of C. jejuni with the O-polysaccharide
biosynthesis pathway of Gram-negative bacteria (11, 16, 18). In
this in vivo bacterial glycosylation system, the O-polysaccharide
linked to the lipid carrier undecaprenolphosphate is synthesized
at the cytoplasmic face of the inner membrane, flipped to the
periplasm, and polymerized. Subsequently, the O-polysaccharide
is transferred by PglB from the lipid to a carrier protein, resulting
in the synthesis of the O-polysaccharide–protein conjugate (18).
Therefore, the glycoprotein of interest can be produced in a non-
pathogenic Gram-negative bacterium coexpressing the enzymes
required for the synthesis of the O-polysaccharide, PglB, and a
carrier protein. Among the advantages of this novel technology in
comparison with the traditional chemical methods used to pro-
duce glycoconjugates, we can highlight the versatility of the sys-
tem, allowing the synthesis of a panel of glycoproteins with differ-
ent sugar compositions, and the fact that the glycoproteins can be
purified in one step from the periplasm of Gram-negative bacteria
without the need for culturing pathogenic or slow-growing bac-
teria. Additionally, no chemical treatments are required for the
isolation and cross-linking of the O-polysaccharide to the carrier
protein, resulting in more homogeneous products that may facil-
itate the standardization of the antigens.
We previously produced and fully characterized the recombi-
nant glycoprotein OAg-AcrA, consisting of the O-polysaccharide
of B. abortus (OAg) covalently linked to the carrier protein AcrA
(16). OAg-AcrA was used to develop new indirect immunoassays
for the diagnosis of human and bovine brucellosis by coupling the
antigen to magnetic beads or ELISA plates and using different
detection systems (spectrophotometric, electrochemical, or fluo-
rescent detection) and different types of samples (14, 15, 19). We
have demonstrated that the OAg-AcrA-based assays have excel-
lent performance for the diagnosis of human brucellosis caused by
B. abortus, B. melitensis, and B. suis, the three main human bru-
cellosis agents, despite the small structural differences between the
O-polysaccharides of these species (14).
In this work, we validated the recombinant glycoprotein OAg-
AcrA antigen for diagnosis of porcine brucellosis using serum
samples obtained from experimentally infected and immunized
pigs, as well as naturally infected animals. This new standardized
antigen allowed the development of a highly accurate immunodi-
agnostic test for porcine brucellosis.
MATERIALS AND METHODS
Production and purification of the O-polysaccharide–protein conju-
gate (OAg-AcrA). Production, purification, and characterization of the
recombinant glycoprotein OAg-AcrA was performed as previously de-
scribed (15, 16). Briefly, the Y. enterocolitica O:9 wild-type strain trans-
formed with the plasmids pMAF10 (encoding the C. jejuni OTase PglB)
and pMH5 (encoding the C. jejuni carrier protein AcrA fused to a histi-
dine tag) was grown at 37°C in LBmedium to an optical density at 600 nm
(OD600) of 0.5. AcrA was constitutively expressed, and PglBCj expres-
sion was induced with arabinose 0.2% (wt/vol). Four hours after induc-
tion at 37°C, PglBCj was reinduced by a second addition of arabinose to
maximize the glycosylation of AcrA. Cells were harvested by centrifuga-
tion after 20 h of induction, and periplasmic extracts were prepared by
lysozyme treatment and subjected to Ni2 affinity chromatography.
OAg-AcrA glyco-iELISA development and optimization. Microtiter
plates (Corning number 3590) were coated with OAg-AcrA at 2.5 g/ml.
The antigenwas diluted in 0.05Mcarbonate buffer, pH9.6, and incubated
for 18 h at 4°C. The plates were washed four times in 0.01 M phosphate-
buffered saline, pH 7.2 (PBS), containing 0.2% Tween 20 (PBST) and
blocked with 5% bovine skim milk in PBST (blocking buffer) for 1 h at
37°C. Serum samples were diluted in blocking buffer, added in duplicate,
and incubated for 1 h at 37°C. Positive- and negative-control samples
were included in each plate. Subsequently, horseradish peroxidase
(HRP)-labeled goat anti-porcine IgG (Abcam) antibodies diluted in
blocking buffer were added and incubated for 1 h at 37°C. Between reac-
tion steps, the plates were washed three times with PBST to remove excess
reagents. After incubation with the substrate (0.36% H2O2 and 0.01%
3,3=,5,5=-tetramethylbenzidine [TMB] in 0.1 M citric acid, pH 4.2) for 3
min at room temperature, the reaction was stopped with 0.16 M H2SO4
and the absorbance was determined at 450 nm using a plate reader (DTX
880 Multimode Detector; Beckman Coulter, Inc.). Optimization of the
assaywas performed as previously described (15). Based on these analyses,
the optimal antigen concentration was 2.5 g/ml (125 ng/well) and the
optimal dilutions of the samples and conjugate were 1:200 and 1:5,000,
respectively. These established parameters were used to test all the sam-
ples.
Other tests. The BPAT and FPAwere performed by the National Bru-
cellosis Reference Laboratory (DILAB-SENASA) of Argentina as previ-
ously described (20, 21). For the BPAT, any degree of agglutination was
considered positive, and for the FPA, a reactivity value of85 milipolar-
ization units (mP) was considered positive. The RBT and CFT were per-
formed by the Unidade Estratégica de Investigação e Serviços em
Produção e Saúde Animal, Instituto Nacional de Investigação Agrária e
Veterinária (UEISPSA-INIAV) of Portugal as described previously (21).
Porcine samples. To evaluate the performance of the assay, 563 serum
samples obtained from the following animal groups were analyzed.
Ethics statement.All the samples analyzed in this studywere provided
by the DILAB-SENASA and UEISPSA-INIAV, and all the studies with
animals were done in accordance with institutional animal guidelines and
approved by the local regulatory agencies (CICUAE-UNSAM).
(i) Experimentally infected animals. Six animals (twomales and four
females) 4 months of age were intramuscularly inoculated with 5  106
CFUofB. suis 1330, and serum sampleswere obtained immediately before
infection and 16 and 60 days postinfection. At 60 days postinfection, the
animals were slaughtered, and samples from different organs (spleen,
liver, lymph nodes, thymus, and tonsil) and tissues (whole blood) were
obtained.
(ii) Experimentally immunized animals. Twelve animals (six males
and six females) 6 months of age were intramuscularly inoculated with
5 109 heat-killed bacteria (B. suis 1330 bacteria killed by heating for 1 h
at 60°C), and serum samples were obtained immediately before and 30
days after inoculation.
(iii) Naturally infected animals. Serum samples were obtained from
animals coming from brucellosis-positive pig farms in which the circula-
tion of B. suis was confirmed by isolation. Thirty-one samples were from
an Argentinean farm, among which two animals were culture positive for
B. suis biovar 1, and 10 samples were from a farm in Portugal in which all
the animals were culture positive for B. suis biovar 2.
(iv) Serologically positive animals. Serologically positive samples
(positive by at least two different serological tests) were obtained from
animals from herds with a history of brucellosis. Sera from 120 pigs
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from Argentina were positive by BPAT and FPA, and 26 serum samples
from Portugal were positive by RBT and CFT.
(v) Serologically negative animals. Serum samples were obtained
from serologically negative animals from Argentina; this group included
samples obtained from animals coming from herds with a history of bru-
cellosis (NEG exposed) (n  122) or from brucellosis-free herds (NEG
unexposed) (n 32) and from Canada, a country free of porcine brucel-
losis (n 180).
Positive- and negative-control sera included in each assay run. The
positive-control serum was obtained from a culture-positive (B. suis bio-
var 1) and serologically positive (BPAT, positive; FPA, 96 mP) animal.
The negative-control serum was obtained from a noninfected animal
(BPAT, negative; FPA, 59 mP) coming from a brucellosis-free herd.
The serum samples from Argentina and Canada were provided by the
DILAB-SENASA. The sera fromPortugal were provided by theUEISPSA-
INIAV.
Bacterial isolation and typing. Organ samples were cut into pieces,
disaggregated, and plated directly in petri dishes containing tryptic soy
agar (TSA) supplemented with 20 mg/liter vancomycin (Sigma-Aldrich),
100 mg/liter cycloheximide (ICN Biomedicals), 10 U/ml bacitracin (Sig-
ma-Aldrich), 5 mg/ml nalidixic acid (Sigma-Aldrich), 6,000 U/ml poly-
myxin B (Sigma-Aldrich), and 1mg/ml amphotericin B (Sigma-Aldrich).
The results were expressed as CFU per gram of tissue. Whole-blood sam-
ples (5 ml) were inoculated directly into biphasic Ruiz-Castañeda bottles
containing TSA supplemented as described above. The bottles and plates
were incubated at 37°C until the appearance of bacterial growth. Colonies
suspected of being Brucella bymacroscopic appearance were identified by
Gram staining and typing by multiplex PCR (Bruce-ladder) (22). The
results were expressed as positive or negative for isolation of Brucella.
Western blotting. Nonglycosylated AcrA and the glycoprotein OAg-
AcrA were subjected to SDS-10% PAGE and transferred to nitrocellulose
membranes by semidry electroblotting. Immunoblotting was performed
with the indicated serum samples at a 1:1,000 dilution in the blocking
buffer (20 mM Tris-HCl, 150 mM NaCl, pH 7.5, 0.1% Tween 20, 5%
caprine skimmilk). Bound antibodies were visualized using HRP-labeled
goat anti-porcine IgG (Abcam) secondary antibodies and enhanced
chemiluminescence (SuperSignal West Pico chemiluminescent substrate
detection reagents; Pierce Chemical Co.) according to themanufacturer’s
instructions.
Data analysis. Reactivity values were relativized with respect to the
absorbance at 450 nm (A450) of the positive-control serum included in
each assay run. Relative reactivity (RR) was calculated as follows: RR 
mean A450 of the test sample/mean A450 of the positive control. Dot plot,
receiver-operating characteristic (ROC) (23, 24), two-graph ROC (TG-
ROC) (a plot of the diagnostic sensitivity and specificity of the assay as a
function of the cutoff values) (25), andMann-Whitney test analyses were
performed using GraphPad Prism software (version 5.01 for Windows;
GraphPad, San Diego, CA, USA).
RESULTS
OAg-AcrA as an antigen for diagnosis of porcine brucellosis.
Since the O-polysaccharide of LPS is the immunodominant anti-
gen in “smooth” brucella infections, and because serological as-
says based on the detection of antibodies against this antigen
proved to be the most sensitive tests, we postulate that the recom-
binant glycoprotein OAg-AcrA would be an excellent tool for the
diagnosis of porcine brucellosis. As a proof of concept and to
demonstrate the usefulness of OAg-AcrA for the serodiagnosis of
the disease, we developed an indirect ELISA coupling the antigen
to microtiter plates (glyco-iELISA; see Materials and Methods)
and analyzed serum samples obtained from experimentally in-
fected and immunized pigs, as well as naturally infected animals.
First, six animals were intramuscularly inoculatedwith 5 106
CFU of B. suis 1330, and serum samples were obtained immedi-
ately before infection and 16 and 60 days postinfection. In all
cases, the infectionwas retrospectively confirmed bymicrobiolog-
ical isolation of B. suis from different organs and tissues at the
necropsies (Table 1). All preinfection sampleswere negative by the
glyco-iELISA, and increasing reactivity values were observed at 16
and 60 days postinfection (Fig. 1A and Table 2). Animal 1 pre-
sented a higher basal reactivity value than the other animals. At 16
days postinfection, samples obtained from animals 1, 4, and 6
were negative by BPAT and FPA, and one sample (animal 3) was
negative only by FPA. Twoof these samples (animals 1 and 3)were
positive by glyco-iELISA, using a cutoff value of 0.56 (see below).
At 60 days postinfection, all the samples were positive by glyco-
iELISA, while a serum sample from animal 4 was negative by
BPAT (Table 2). These results indicate that by using the OAg-
AcrA antigen it is possible to discriminate clearly between infected
and noninfected animals. To evaluate the specificity of the reac-
tion, preinfection and 60-day-postinfection sera were also an-
alyzed by Western blotting against the nonglycosylated and
glycosylated forms of AcrA (Fig. 1B). Reactivity against the
glycoprotein was observed with the samples obtained at 60 days
postinfection, but not with the preinfection samples obtained
from the same animals. None of the samples was reactive against
the nonglycosylated form of AcrA, indicating that the antibody
response detected was specifically directed toward the O-polysac-
charide moiety of the glycoprotein. Additionally, we analyzed se-
rum samples obtained from experimentally immunized animals.
Twelve animals were inoculated with 5  109 B. suis 1330 heat-
killed bacteria, and sera were obtained immediately before and 30
days after the inoculation. As expected, preinoculation samples
were negative by glyco-iELISA and BPAT (Table 3). At 30 days
postinoculation, all the samples except one (animal 1) were posi-
tive by glyco-iELISAusing a cutoff value of 0.56 (see below); at this
time, all the samples were positive by BPAT, but 10 out of 12 were
negative by FPA (Table 3). In the case of animal 1 (positive by
BPAT but negative by glyco-iELISA), it is possible that at this early
time of sampling (30 days postinoculation) the sample had a low
titer of specific IgG antibodies. Because the glyco-iELISA detects
specific IgG antibodies and the BPAT detects specific IgM and IgG
antibodies, this could explain the differences observed.
To evaluate further the usefulness of the antigen for the diag-
nosis of porcine brucellosis, we analyzed serum samples obtained
from animals coming from naturally infected herds. Thirty-one
TABLE 1 Bacterial isolation from organs and tissues obtained from
experimentally infected animals
Animal
no.
Bacterial isolation from organs and tissues (CFU/g)a
Spleen Liver GLN ILN SLN PLN Thymus Tonsil Blood
1 237 1 239 NEG 1 NEG ND ND NEG
2 769 9 634 9 UNC 6 11 ND POS
3 52 5 132 5 29 2 ND ND POS
4 1,440 17 ND 14 20 ND ND ND POS
5 40 2 72 10 553 ND NEG ND POS
6 145 40 916 25 2,200 18 UNC UNC POS
a Bacterial isolation from organs or tissues obtained from experimentally infected
animals at 60 days postinfection. GLN, gastrosplenic lymph nodes; ILN, inguinal lymph
nodes; SLN, submandibular lymph nodes; PLN, prepectoral lymph nodes; NEG,
negative isolation; POS, positive isolation; ND, not done (no sample available); UNC,
uncountable CFU. For blood samples, 5 ml was inoculated directly into Ruiz-Castañeda
bottles.
Cortina et al.
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samples were obtained from a pig farm in Argentina (animals 1 to
31), amongwhich 2 animalswere culture positive forB. suisbiovar
1, and 10 samples from a farm in Portugal (animals 32 to 41)
where all the animals were culture positive for B. suis biovar 2
(Table 4). Samples 1 to 5were obtained from animals with signs of
infection, such as a high percentage of abortions, increased neo-
natal mortality, and infertility; in two of these pigs, B. suis biovar 1
was isolated from blood (Table 4). It is well known that B. suis can
spread quickly in a pig farm with no history of brucellosis (3);
thus, we decided to include in the analysis serum samples obtained
from the remaining 26 pigs (animals 6 to 31) that were in close
contact with the five infected animals. All the analyzed samples
except two showed high reactivity values by glyco-iELISA, and
these results were in complete agreement with those obtained by
BPAT and FPA (Table 4). Finally, in order to determine the diag-
nostic value of the OAg-AcrA antigen for diagnosis of the disease
in pigs infected with B. suis biovar 2, we analyzed the 10 samples
obtained from animals with positive isolation of B. suis biovar 2.
All the samples showed high reactivity by glyco-iELISA, in
FIG 1 OAg-AcrA recombinant glycoprotein as a novel antigen for the
diagnosis of porcine brucellosis. Six animals were intramuscularly inocu-
lated with 5  106 CFU of B. suis 1330, and serum samples were obtained
before the infection and 16 and 60 days postinfection. (A) Glyco-iELISA
analysis of the samples. The reactivity values are relative to the positive
control included in each assay run. (B) Western blot analysis of the serum
samples obtained before infection (Pre) and 60 days postinfection (Post).
For animal 1, the analyzed sample corresponded to that obtained at 16 days
postinfection. NG, nonglycosylated AcrA; G, glycosylated AcrA (OAg-
AcrA). The positions of molecular mass standards (in kDa) are indicated
on the left. The arrows on the right indicate the migration positions of
nonglycosylated AcrA.
TABLE 2 Serological test results for samples obtained from experimentally infected animalsa
Animal no.
Test result
Preinfection
Postinfection
16 days 60 days
BPATb FPA (mP)c Glyco-iELISA BPAT FPA (mP) Glyco-iELISA BPAT FPA (mP) Glyco-iELISA
1 NEG 70 0.25 NEG 80 1.1 ND ND ND
2 NEG 72 0.07 POS 100 0.86 POS 126 1.23
3 NEG 68 0.08 POS 75 0.57 POS 198 1.26
4 NEG 71 0.07 NEG 75 0.49 NEG 96 1.09
5 NEG 64 0.06 POS 95 0.94 POS 181 1.25
6 NEG 64 0.07 NEG 75 0.26 POS 121 1.21
a Analysis of serum samples obtained from animals intramuscularly infected with 5 106 CFU of B. suis 1330.
b BPAT, NEG, negative; POS, positive, ND, not done.
c FPA cutoff value,85 mP.
TABLE 3 Serological test results for samples obtained from
experimentally immunized animalsa
Animal no.
Test result
Preinoculation 30 days postinoculation
BPATb Glyco-iELISA BPAT
FPA
(mP)c Glyco-iELISA
1 NEG 0,07 POS 70 0.32
2 NEG 0,07 POS 67 1.40
3 NEG 0,07 POS 72 1.29
4 NEG 0,07 POS 83 1.81
5 NEG 0,07 POS 52 1.20
6 NEG 0,07 POS 71 0.68
7 NEG 0,08 POS 68 0.74
8 NEG 0,07 POS 74 1.17
9 NEG 0,08 POS 106 1.90
10 NEG 0,08 POS 73 0.65
11 NEG 0,08 POS 90 1.77
12 NEG 0,19 POS 75 1.60
a Serological test results for serum samples obtained from animals intramuscularly
inoculated with 5 109 B. suis 1330 heat-killed bacteria.
b BPAT, NEG, negative; POS, positive.
c FPA cutoff value,85 mP.
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complete agreement with the results obtained by RBT and CFT
(Table 4).
Taken together, these results demonstrate the potential of the re-
combinant glycoprotein OAg-AcrA as a sensitive and specific diag-
nostic tool for porcine brucellosis caused by B. suis biovars 1 and 2.
OAg-AcrA antigen validation. To further validate the antigen,
a larger panel of positive and negative serum samples (n  525)
was analyzed by glyco-iELISA. The group of negative reference
samples (NEG) included serologically negative samples obtained
from animals coming from herds free of the disease (NEG unex-
posed; n  32) and herds with a history of brucellosis (NEG ex-
posed; n 122) and from Canada, a country free of porcine bru-
cellosis (n 180). The group of positive reference samples (POS)
included sera obtained from culture-positive animals (n  6 ex-
perimentally infected animals; n  12 animals naturally infected
with B. suis biovar 1 or 2) and samples obtained from animals in
which the infection was not confirmed by bacteriological culture
but with positive results by at least two serological tests (n 147
samples seropositive by BPAT and FPA from Argentina; n  26
samples seropositive by RBT and CFT from Portugal). The glyco-
iELISA reactivity values obtained with the POS and NEG groups
of samples are outlined in the dot plot diagram shown in Fig. 2A.
Almost no overlap between the POS and NEG groups of samples
was observed; only one sample from theNEG-exposed group gave
a reactivity value that overlapped those obtained with the POS
group. These results indicate that, using the OAg-AcrA antigen, it
is possible to discriminate clearly between brucellosis-positive an-
imals and noninfected animals.
To evaluate the diagnostic performance of the glyco-iELISA, a
ROC analysis was performed. ROC analysis was carried out using
as positive and negative reference samples the POS and NEG
groups described for the dot plot. Based on the ROC results, the
area under the ROC curve (AUC) value was 0.9999 (95% confi-
dence interval [CI], 0.9997 to 1.000), indicating that the test is
highly accurate for the diagnosis of porcine brucellosis. With the
objective of selecting the cutoff points that maximize the diagnos-
tic sensitivity (Se) and/or specificity (Sp) of the test, a plot of the
diagnostic Se and Sp as a function of the cutoff values (TG-ROC
plot) was performed (Fig. 2B). This analysis allowed us to de-
termine the cutoff value for which the diagnostic Se was 100%
(cutoff  0.56; Sp  99.7%) and the cutoff value that gave a
100% Sp (cutoff 0.78; Se 98.4%). The cutoff value that con-
currently optimized the Se and Sp coincided with the cutoff for
which the maximum Se was reached (cutoff  0.56) (Fig. 2B,
dotted line).
Finally, we analyzed by glyco-iELISA serum samples obtained
from animals coming from farms with a history of brucellosis but
that did not meet the criteria established here for the selection of
serologically positive samples (Table 5). These samples were pos-
itive in only one of the serological tests. Seven out of 12 samples
that were BPAT positive/FPA negative were confirmed by the
glyco-iELISA, whereas the three samples that were BPAT nega-
tive/FPA positive all had positive results by glyco-iELISA.
Overall, our results demonstrate that the recombinant glyco-
protein-based assay is highly accurate for diagnosis of porcine
brucellosis, improving the diagnostic performance of current se-
rological tests.
DISCUSSION
The hallmark of infection with smooth Brucella strains is the in-
duction of high titers of antibodies against the immunodominant
O-polysaccharide section of smooth LPS (sLPS). That is why the
most sensitive and cost-effective way to diagnose the disease is by
means of serological assays (26, 27). For these reasons, and due to
the previously demonstrated excellent diagnostic performance of
the recombinant glycoprotein OAg-AcrA for diagnosis of bovine
TABLE 4 Serological test results for samples obtained from animals
coming from naturally infected herdsa
Animal no.
Result
BPATb
FPA
(mP)c Glyco-iELISA Isolation
1 POS 175 1.22 B. suis biovar 1
2 POS 230 1.24 B. suis biovar 1
3 POS 247 1.28 NEG
4 POS 258 1.24 NEG
5 POS 187 1.24 NEG
6 POS 250 1.25 NDd
7 POS 126 1.18 ND
8 NEG 72 0.41 ND
9 POS 254 1.25 ND
10 POS 126 1.12 ND
11 POS 148 1.22 ND
12 POS 235 1.25 ND
13 POS 273 1.22 ND
14 POS 250 1.22 ND
15 NEG 67 0.25 ND
16 POS 257 1.24 ND
17 POS 230 1.25 ND
18 POS 120 1.21 ND
19 POS 265 1.27 ND
20 POS 270 1.26 ND
21 POS 235 1.17 ND
22 POS 103 1.19 ND
23 POS 215 1.21 ND
24 POS 265 1.22 ND
25 POS 253 1.23 ND
26 POS 153 1.24 ND
27 POS 255 1.27 ND
28 POS 230 1.31 ND
29 POS 143 1.23 ND
30 POS 235 1.25 ND
31 POS 242 1.28 ND
32 POS ND 1.17 B. suis biovar 2
33 POS ND 1.15 B. suis biovar 2
34 POS ND 1.14 B. suis biovar 2
35 POS ND 1.15 B. suis biovar 2
36 POS ND 1.11 B. suis biovar 2
37 POS ND 1.09 B. suis biovar 2
38 POS ND 1.13 B. suis biovar 2
39 POS ND 1.25 B. suis biovar 2
40 POS ND 1.22 B. suis biovar 2
41 POS ND 1.21 B. suis biovar 2
a Serological test results for serum samples obtained from animals coming from pig
farms with at least one animal with positive isolation of B. suis.
b BPAT, NEG, negative; POS, positive.
c FPA cutoff value,85 mP.
d ND, not done. Brucella isolation from animals 6 to 31 was not attempted because no
tissue and/or organs samples were available. None of these animals showed signs of
illness up to the time of sampling.
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and humanbrucellosis (14, 15), we decided to evaluate the antigen
for the diagnosis of porcine brucellosis.
In this work, we validated the recombinant glycoprotein OAg-
AcrA for diagnosis of porcine brucellosis by coupling the antigen
to microtiter plates (glyco-iELISA) and using different sample
panels. All glyco-iELISA parameters (antigen concentration and
dilutions of sample and conjugate) were optimized as indicated in
Materials and Methods. Initially, we analyzed serum samples ob-
tained from experimentally infected and immunized pigs, as well
as fromnaturally infected animals confirmedby isolation ofB. suis
biovar 1 or 2, allowing us to evaluate the performance of OAg-
AcrA with a well-characterized panel of samples. The results ob-
tained indicated that with this antigen, it is possible to discrimi-
nate unambiguously between infected and noninfected animals.
By immunoblotting, we confirmed that the detected antibodies
reacted specifically against the O-polysaccharide section of the
glycoprotein, ruling out any potential interference from the car-
rier protein. Then, to further validate the antigen, a large panel of
positive and negative samples (including culture-positive and se-
rologically positive and negative samples) was evaluated and a
ROC analysis was performed (23–25). The AUC (AUC 0.9999;
95% CI, 0.9997 to 1.000) indicated that the glyco-iELISA is a
highly accurate test to diagnose porcine brucellosis. Based on the
ROC analysis, high values of diagnostic Se and Spwere obtained at
the selected cutoffs, as well as a narrow intermediate range of
reactivity values, which correlates with the low level of overlap-
ping observed between the reactivity values of negative and posi-
tive samples. Finally, we analyzed serum samples obtained from
animals coming from herds with a history of brucellosis that did
not meet the criteria established here for the selection of serolog-
ically positive samples (i.e., positive by at least two serological
tests). The results obtainedwith these samples, togetherwith those
obtained with the samples from experimentally infected and im-
munized animals, indicate that the glyco-iELISAmay improve the
diagnostic performance of the BPAT and FPA used for diagnosis
of porcine brucellosis.
Historically all the serological tests for the diagnosis of porcine
brucellosis have been based on those developed for bovine brucel-
losis, and therefore, they use as antigens whole bacteria (BPAT,
RBT, and CFT), bacterial extracts enriched in sLPS (iELISA and
cELISA), or a purified22-kDa fragment of theO-polysaccharide
of B. abortus sLPS (FPA). To obtain these antigens, level 3 bio-
safety facilities and multiple purification steps, in particular for
sLPS and the 22-kDa O-polysaccharide fragment, are required.
These procedures do not allow homogeneous and standardized
batches of the antigens to be obtained, a problem still unresolved
for all serological tests currently used for the diagnosis of human
and animal brucellosis. Recently, a series of synthetic antigens
FIG 2 Dot plot and ROC analysis of glyco-iELISA results. (A) Dot plot anal-
ysis. Serum samples obtained from positive (POS) and negative (NEG) ani-
mals were tested by glyco-iELISA as indicated in Materials and Methods. The
POS group included serum samples obtained from culture-positive and sero-
logically positive (by at least two different serological tests) animals. The NEG
group included samples obtained from animals coming from herds with a
history of brucellosis (NEG exposed); herds without any history of the disease
(NEG unexposed); and herds from Canada, a brucellosis-free country (NEG
free country). The mean and standard deviation for each group are indicated:
POS, 1.43  0.33; NEG exposed, 0.21  0.09; NEG unexposed, 0.13  0.05;
NEG free country, 0.14  0.04. ***, P 	 0.0001; Mann-Whitney test. (B)
TG-ROC plot of the results. ROC analysis was carried out using as a positive
reference samples the sera of the POS group and as a negative reference sam-
ples of the sera of the three NEG groups described for the dot plot in panel A.
The dotted and dashed lines in the dot plot and TG-ROC plots indicate the
cutoff values for which maximal diagnostic Se or Sp, respectively, were
achieved. The two cutoff values represent the bounds of an intermediate range
(IR) of reactivity values (shaded areas). (Inset) Se and Sp values obtained for
the two cutoff values. The cutoff value that concurrently optimizes Se and Sp
coincides with the cutoff value for which maximal Se was achieved (0.56;
dotted line).
TABLE 5 Analysis by glyco-iELISA of samples positive by BPAT or
FPAa
Animal no.
Test result
BPATb FPA (mP)c Glyco-iELISA
1 POS 55 0.81
2 POS 59 0.22
3 POS 69 0.95
4 POS 76 0.88
5 POS 79 0.54
6 POS 65 0.52
7 POS 57 1.56
8 POS 62 1.51
9 POS 74 0.78
10 POS 82 0.77
11 POS 56 0.39
12 POS 74 0.44
13 NEG 137 1.94
14 NEG 185 0.98
15 NEG 202 2.20
a These samples did not meet the criteria established in this study for the selection of
positive samples.
b BPAT, NEG, negative; POS, positive.
c FPA cutoff value,85 mP.
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based on the structure of the O-polysaccharide have been ob-
tained and evaluated for diagnosis of bovine brucellosis, but with
poor diagnostic performance in terms of sensitivity (28). Our
glyco-iELISA proved to have high diagnostic performance, and
additionally, production of the antigen can be easily scaled up
from bacterial fermentations without the need for culturing
pathogenic or slow-growing bacteria. Glycoengineering technol-
ogy also facilitates the purification of the antigen, since it can be
purified in a one-step process from periplasmic extracts by metal
chelate affinity chromatography. Therefore, this technology re-
duces the upstream and downstream processing costs and makes
the entire process more biosecure, since nonpathogenic bacteria
are used. Additionally, the glycoengineering method overcomes
many of the inherent disadvantages of the traditional chemical
methods for the production of O-polysaccharide–protein conju-
gates (29). The production of OAg-AcrA does not require the
purification of sLPS from the bacterium of interest. Furthermore,
no chemical treatments are required either to release the O-poly-
saccharide from the lipid A core or to cross-link the carbohydrate
to the carrier protein. In our system, all these steps are controlled
in vivo by the bacteria, allowing the production of large homoge-
neous batches of antigen that in the future may facilitate the elab-
oration of a standardized reference antigen, with important im-
plications for diagnosis of smooth brucellosis in humans and the
animal species that constitute the reservoir of the disease. In this
sense, we propose the recombinant glycoprotein OAg-AcrA as a
universal antigen for diagnosis of smooth brucellosis. So far, we
have validated the antigen for the diagnosis of brucellosis in hu-
mans (14), cattle (15), and pigs (this work). The versions of glyco-
iELISA for goats and camels are under development. Furtherwork
will be required to assess the usefulness of the antigen for diagnosis
of the disease in other animal species, as well as brucellosis caused
by the new atypical strains reported recently.
In view of the excellent diagnostic performance in terms of
sensitivity and specificity, we propose the glyco-iELISA as an im-
proved test for diagnosis of porcine brucellosis. The excellent per-
formance of the test in terms of diagnostic specificity could be
explained by the fact that only the outer moiety of sLPS (i.e., the
O-polysaccharide) is coupled to the carrier protein. Current tests
have reduced serospecificity due to the presence of cross-reactive
antibodies against common epitopes present in the core polysac-
charide and lipid A of different bacteria. B. abortus and Y. entero-
colitica O:9 have almost identical O-polysaccharide structures. B.
abortus O-polysaccharide contains both A and M epitopes, with
approximately 98% A epitope, while Y. enterocoliticaO:9 O-poly-
saccharide is comprised solely of the A variant (30–32). False-
positive serological reactions due to cross-reactivity linked to
shared epitopes associated with the O-polysaccharide of Brucella
and other bacteria could occur, but they constitute a relevant
problem only in those regions with low prevalence of brucellosis
or where the disease has been eradicated or controlled. In this
scenario, a positive result should be confirmed by anothermethod
with high specificity (near 100%) but also with high sensitivity at
the selected cutoff for which maximal specificity is achieved. In
theory, themost specificmethods are those based on non-O-poly-
saccharide antigens, but so far, all these methods suffer from very
low sensitivity values at the cutoff that gives 100% specificity (26,
33, 34), and a cutoff yielding a specificity near 100% should always
be applied when validating swine brucellosis tests in the context of
low prevalence of the disease and/or the existence of false-positive
serological reactions (26, 33, 34).
Here, we validated a recombinant glyco-iELISA and propose it
as the test of choice for diagnosis of porcine brucellosis in regions
with high prevalence of the disease. Although brucellosis has been
eradicated frommany industrialized countries, new foci of disease
continually appear (35). The excellent diagnostic performance of
theOAg-AcrA antigen for diagnosis of brucellosis in different spe-
cies and the fact that the recombinant glycoprotein can be pro-
duced in large homogeneous batches in a standardized way make
it an ideal candidate for further validation as a universal antigen
for diagnosis of smooth brucellosis.
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